MID-TERM SAFETY AND EFFICACY OF UPADACITINIB IN ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: A REAL-LIFE 34-PATIENT MULTICENTER TRIAL Academic Article 2024